Stock SCP SCOPE FLUIDICS S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Scope Fluidics S.A.

Equities

SCP

PLSCPFL00018

Biotechnology & Medical Research

Market Closed - Warsaw S.E.
Other stock markets
 11:55:57 2024-05-02 am EDT 		5-day change 1st Jan Change
162.4 PLN -1.46% Intraday chart for Scope Fluidics S.A. -2.29% -17.14%
2023 Scope Fluidics S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
2023 Scope Fluidics S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI

Valuation

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Capitalization 1 33.41 34.56 138.9 362.6 366.4 565.6
Enterprise Value (EV) 1 20.34 25.88 120.6 336.9 361.8 236.5
P/E ratio -8.01 x -8.53 x -24.3 x -48.9 x -22 x 1.75 x
Yield - - - - - 41.2%
Capitalization / Revenue 18,560 x - - - - 1,400 x
EV / Revenue 11,301 x - - - - 585 x
EV / EBITDA -6.43 x -8.05 x -22.5 x -52.5 x -36.8 x -9.55 x
EV / FCF -12.6 x -9.5 x -55.1 x -74.2 x -12.9 x 43.1 x
FCF Yield -7.92% -10.5% -1.82% -1.35% -7.73% 2.32%
Price to Book 1.98 x 2.71 x 7.56 x 11 x 25.1 x 1.7 x
Nbr of stocks (in thousands) 2,304 2,304 2,315 2,686 2,686 2,726
Reference price 2 14.50 15.00 60.00 135.0 136.4 207.5
Announcement Date 5/29/18 5/29/19 5/28/21 5/28/21 5/31/22 3/1/23
1PLN in Million2PLN
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net sales 1 0.0018 - - - - 0.404
EBITDA 1 -3.161 -3.217 -5.37 -6.413 -9.835 -24.77
EBIT 1 -4.112 -4.188 -6.329 -7.399 -10.25 -25.23
Operating Margin -228,432.06% - - - - -6,246.04%
Earnings before Tax (EBT) 1 -4.173 -4.073 -6.3 -7.421 -11.72 395.1
Net income 1 -4.173 -4.073 -6.3 -7.421 -16.64 318.5
Net margin -231,810.61% - - - - 78,833.91%
EPS 2 -1.811 -1.759 -2.474 -2.763 -6.193 118.3
Free Cash Flow 1 -1.612 -2.725 -2.19 -4.539 -27.96 5.481
FCF margin -89,537% - - - - 1,356.78%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - 1.72%
Dividend per Share - - - - - 85.57
Announcement Date 5/29/18 5/29/19 5/28/21 5/28/21 5/31/22 3/1/23
1PLN in Million2PLN
Estimates

Balance Sheet Analysis

Fiscal Period: December 2017 2018 2019 2020 2021 2022
Net Debt 1 - - - - - -
Net Cash position 1 13.1 8.68 18.3 25.7 4.62 329
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 -1.61 -2.73 -2.19 -4.54 -28 5.48
ROE (net income / shareholders' equity) -37.2% -27.4% -38.2% -27.8% -61.8% 192%
ROA (Net income/ Total Assets) -20.4% -16.1% -19.2% -13.5% -13.5% -7.91%
Assets 1 20.43 25.37 32.9 55.13 122.9 -4,028
Book Value Per Share 2 7.330 5.530 7.940 12.30 5.430 122.0
Cash Flow per Share 2 5.670 3.750 7.180 9.570 6.730 122.0
Capex 1 0.21 0.08 0.34 0.48 0.12 0.16
Capex / Sales 11,449.33% - - - - 38.37%
Announcement Date 5/29/18 5/29/19 5/28/21 5/28/21 5/31/22 3/1/23
1PLN in Million2PLN
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Bio Diagnostics & Testing

1st Jan change Capi.
SCOPE FLUIDICS S.A. Stock Scope Fluidics S.A.
-17.14% 109M
EXACT SCIENCES CORPORATION Stock Exact Sciences Corporation
-16.10% 11.13B
IOVANCE BIOTHERAPEUTICS, INC. Stock Iovance Biotherapeutics, Inc.
+67.65% 3.6B
GUARDANT HEALTH, INC. Stock Guardant Health, Inc.
-30.20% 2.26B
BGI GENOMICS CO., LTD. Stock BGI Genomics Co., Ltd.
-14.31% 2.16B
VERACYTE, INC. Stock Veracyte, Inc.
-26.03% 1.54B
MARAVAI LIFESCIENCES HOLDINGS, INC. Stock Maravai LifeSciences Holdings, Inc.
+36.95% 1.17B
SEEGENE, INC. Stock Seegene, Inc.
-2.40% 744M
ADAPTIVE BIOTECHNOLOGIES CORPORATION Stock Adaptive Biotechnologies Corporation
-38.57% 432M
CURIOX BIOSYSTEMS CO., LTD Stock Curiox Biosystems Co., Ltd
+13.72% 357M
Bio Diagnostics & Testing
  1. Stock Market
  2. Equities
  3. SCP Stock
  4. Financials Scope Fluidics S.A.